All Comments by Edward Koo

  1. Alpha-synuclein-immunoreactive deposits in human and animal prion diseases.
  2. Peeling plaque. Researchers remain optimistic about a vaccine against Alzheimer's.
  3. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction.
  4. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.
  5. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
  6. Role of the omentum in the treatment of Alzheimer's disease.
  7. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.
  8. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.
  9. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.
  10. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies.
  11. A gene trap insertion reveals that amyloid precursor protein expression is a very early event in murine embryogenesis.
  12. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.
  13. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc.
  14. Copernicus revisited: amyloid beta in Alzheimer's disease.
  15. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease.